about
Promotion of prescription drugs to consumers and providers, 2001-2010The effects of the coverage gap on drug spending: a closer look at Medicare Part DPotential Savings from an Evidence-Based Consumer-Oriented Public Education Campaign on Prescription DrugsModernizing Medicaid Managed Care: Can States Meet the Data Challenges?Improving quality and diffusing best practices: the case of schizophrenia.The effect of Medicare Part D on drug and medical spending.Trends in use of antipsychotics in elderly patients with dementia: Impact of national safety warningsHow the Medicare Part D drug benefit changed the distribution of out-of-pocket pharmacy spending among older beneficiaries.Diffusion of antipsychotics in the US And French markets, 1998-2008Disparities in quality of care among publicly insured adults with schizophrenia in four large U.S. states, 2002-2008The Medicare drug benefit (Part D) and treatment of heart failure in older adults.Effect of multiple pharmacy use on medication adherence and drug-drug interactions in older adults with Medicare Part D.Twelve-month cost-effectiveness of telephone-delivered collaborative care for treating depression following CABG surgery: a randomized controlled trial.Impact of medicare part D plan features on use of generic drugs.Gastroprotective agent underuse in high-risk older daily nonsteroidal anti-inflammatory drug users over timeThe impact of Medicare Part D on medication treatment of hypertension.From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination.A decade of direct-to-consumer advertising of prescription drugs.The impact of Medicare prescription drug coverage on the use of antidementia drugs.Statin use and decline in gait speed in community-dwelling older adultsWhat are cancer centers advertising to the public?: a content analysis.Antipsychotic prescribing: do conflict of interest policies make a difference?Analgesic use for knee and hip osteoarthritis in community-dwelling elders.Impact of Medicare Part D on antidepressant treatment, medication choice, and adherence among older adults with depression.Use of prescription drug samples and patient assistance programs, and the role of doctor-patient communication.Sources of regional variation in Medicare Part D drug spending.Using machine learning to examine medication adherence thresholds and risk of hospitalization.The financial burden from prescription drugs has declined recently for the nonelderly, although it is still high for many.Medicare Part D's effect on the under- and overuse of medications: a systematic review.Where You Live Matters: Quality and Racial/Ethnic Disparities in Schizophrenia Care in Four State Medicaid Programs.Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisoryCollaborative depression care management and disparities in depression treatment and outcomes.Defining Nonmedical Use of Prescription Opioids Within Health Care Claims: A Systematic Review.Coverage and prior authorization of psychotropic drugs under Medicare Part D.Prevalence and correlates of self-reported medication non-adherence among older adults with coronary heart disease, diabetes mellitus, and/or hypertension.Medication errors in older adults: a review of recent publications.Regional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics.Retaining Part D's comprehensive coverage of antidepressants: not a silver bullet.Changes in cholesterol-lowering medications use over a decade in community-dwelling older adults.Who Were the Early Adopters of Dabigatran?: An Application of Group-based Trajectory Models
P50
Q21133699-10AFE4FF-FE5B-4F0B-9B43-1B4A97B2BFDFQ24632713-CE79795E-9BDB-45D6-906C-1FEBC48AB8E7Q29393270-455B7A4C-0070-43CD-A11B-030C5603C6EFQ30990800-1A0847ED-3ED3-411A-A7C6-287730D30377Q33704267-CCAC2B86-5F55-463F-8C24-220216E1C8AFQ33810332-73483444-0DBF-4FC6-9DDC-794BB4F1FC8FQ33888723-CCC1BB52-D84D-42E0-9B1D-296B5BBA413FQ33906706-EB3E3E2F-3D0F-4FDE-80FC-F7137875EA76Q33915286-344A0443-22DC-4419-B671-8ECCD69CA191Q33953271-AA5B30AD-4307-42A5-B488-50939209D65DQ33967679-1642BB51-C590-4AAB-8FCA-41F2C225D58CQ33969482-88404526-6B76-4582-A07B-66C5DAA927D0Q34066880-3084D69E-D80A-4447-A1F0-C7F783F3F239Q34079971-6F514668-37FE-4916-9D70-134EC6B2C8BCQ34389027-EDA53C45-D3EB-45D6-9602-3726C2FE78C1Q34554697-DC1AAC71-77F1-481C-ACA4-65AAEBB23D4AQ34613417-B3CCC065-58B1-45AB-B433-DE1BEE351A2AQ34663545-FE3B331E-7298-48DC-8A54-C77FD24C2DB6Q34690333-D2A5644C-FE75-4E07-A950-1656181D35D2Q34989719-B438B467-D007-4AC1-9912-89C432633765Q35168225-DB48F26C-A2EB-4A52-AA2C-142305EDF972Q35180226-B3679797-5985-4009-94CB-8CF243FC38DAQ35566824-B3E9DA17-E2F0-4144-B0A8-50B906CEF3B4Q35602002-42F02901-DFB1-44D5-B4D2-1485ACCE6E50Q35606857-61C7D492-4A88-448B-9E46-7C9186ACC25BQ35773656-36A0C45A-61CB-42B3-A51F-3707A21074A6Q35855191-115CDD33-7226-4B4A-ADB6-8DDC78F26E6CQ36070889-D947EB48-5E39-440A-9B37-43D81944F93CQ36105740-4C565F98-C2B5-420C-8C9B-8973585527F8Q36144487-8B571100-D976-4E3C-AD22-6EF83C60B4AFQ36201085-3BF86236-C9C2-41B9-AD32-A49FC52BF31EQ36466389-8B29D370-3063-4F78-A7C1-ED82C98E2FBCQ36530625-DF3C63BA-45BB-4842-8D2D-8533D58D84B2Q36746123-83706E6F-719B-44E2-A014-350CCAE68F71Q36751595-18B6DA3F-51A1-43BF-AE84-69CEDE0493FFQ36869080-6213ED04-9AA4-440A-8827-F7A1EEB1F694Q36926903-8C411930-FA88-4C06-BE4E-D08CD5F87716Q36930720-661E85B1-2D32-40D5-8CF1-AEDCAFA2AE06Q37001217-BCEA3370-264F-4DC4-BED2-DEB7EB2EDB30Q37004184-0636F251-CF7D-4A13-AC25-65A59FE2DB25
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Julie Donohue
@ast
Julie Donohue
@en
Julie Donohue
@es
Julie Donohue
@fr
Julie Donohue
@nl
Julie Donohue
@sl
type
label
Julie Donohue
@ast
Julie Donohue
@en
Julie Donohue
@es
Julie Donohue
@fr
Julie Donohue
@nl
Julie Donohue
@sl
prefLabel
Julie Donohue
@ast
Julie Donohue
@en
Julie Donohue
@es
Julie Donohue
@fr
Julie Donohue
@nl
Julie Donohue
@sl
P106
P1153
7202771415
P21
P31
P496
0000-0003-2418-6017